Hepatitis C, interferon α and depression: Main physiopathologic hypothesis;Hépatite C, interféron α et dépression: Principales hypothèses physiopathologiques

Encephale

Volumn 31, Issue 3, 2005, Pages 349-357

  Vignau, J ^a   Karila, L ^a   Costisella, O ^a   Canva, V ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Cytokine; Depression; Hepatitis C virus; Interferon alpha

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN; SEROTONIN;

BLOOD BRAIN BARRIER; DEPRESSION; DISEASE ASSOCIATION; HEPATITIS C; HUMAN; HYPOTHESIS; MOOD DISORDER; NONHUMAN; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW; SEROTONINERGIC SYSTEM; THYMUS DISEASE;

EID: 22644447406     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0013-7006(05)82400-5     Document Type: Article

References (95)

1. ABE S, HORI T, SUZUKI T et al. Effects of chronic administration of Interferon alpha A/D on serotonergic receptors in rat brain. Neurochem Res 1999; 24 (3): 359-63.
2. BASARAN MM, BARLAN IB, TUKENMEZ F et al. Effect of interferon-alpha therapy on serum IgE, IL-4, and sCD23 levels in childhood asthma. J Asthma 1995; 32 (3): 215-20.
3. BELL J, BATEY RG, FARRELL GC et al. Hepatitis C virus in intravenous drug users. Med J Aust 1990; 153 (5): 274-6.
4. BIRMANNS B, SAPHIER D, ABRAMSKY O. Alpha-interferon modifies cortical EEG activity: dose-dependence and antagonism by naloxone. J Neurol Sci 1990; 100 (1-2): 22-6.
5. BLALOCK JE, SMITH EM. Human leukocyte Interferon: structural and biological relatedness to adrenocorticotropic hormone and endorphins. Proc Natl Acad Sci USA 1980; 77 (10): 5972-4.
6. BLALOCK JE, STANTON JD. Common pathways of interferon and hormonal action. Nature 1980; 283 (5745): 406-8.
7. BOCCI V. Central nervous system toxicity of interferons and other cytokines. J Biol Regul Homeost Agents 1988; 2 (3): 107-18.
8. BONACCORSO S, MARINO V, PUZELLA A et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22 (1): 86-90.
9. BONKOVSKY HL, WOOLLEY JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999; 29 (1): 264-70.
10. BORDEN EC, PARKINSON D. A perspective on the clinical effectiveness and tolerance of interferon-alpha. Semin Oncol 1998; 25 (Suppl 1): 3-8.
11. BOURAT L, LARREY D, MICHEL H. Attempted suicide during treatment of chronic viral hepatitis C with interferon. A propos of 2 cases. Gastroenterol Clin Biol 1995; 19 (12): 1063.
12. BROWN RR, OZAKI Y, DATTA SP et al. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol 1991; 294: 425-35.
13. CAPURON L, RAVAUD A, GUALDE N et al. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 2001; 26 (8): 797-808.
14. CAREY MP, CAREY KB, WEINHARDT LS et al. Behavioral risk for HIV infection among adults with a severe and persistent mental illness: patterns and psychological antecedents. Commun Ment Health J 1997; 33 (2): 133-42.
15. CARPINIELLO B, ORRU MG, BAITA A et al. Mania induced by withdrawal of treatment with interferon alfa. Arch Gen Psychiatry 1998; 55 (1): 88-9.
16. CASSIDY EM, O'KEANE V. Depression and interferon-alpha therapy. Br J Psychiatry 2000; 176: 494.
17. CHARLTON BG. The malaise theory of depression: major depressive disorder is sickness behavior and antidepressants are analgesic. Med Hypotheses 2000; 54 (1): 126-30.
18. CIVIDINI A, PISTORIO A, REGAZZETTI A et al. Hepatitis C virus infection among institutionalised psychiatric patients: a regression analysis of indicators of risk. J Hepatol 1997; 27 (3): 455-63.
19. COLLINS JM, RICCARDI R, TROWN P et al. Plasma and cerebrospinal fluid pharmacokinetics of recombinant interferon alpha A in monkeys: comparison of intravenous, intramuscular, and intraventricular delivery. Cancer Drug Deliv 1985; 2 (4): 247-53.
20. CRNIC LS, SEGALL MA. Behavioral effects of mouse interferons-alpha and -gamma and human interferon-alpha in mice. Brain Res 1992; 590 (1-2): 277-84.
21. CURRELI S, ROMERIO F, MIRANDOLA P et al. Human primary CD4+T cells activated in the presence of IFN-alpha 2b express functional indoleamine 2,3-dioxygenase. J Interferon Cytokine Res 2001; 21 (6): 431-7.
22. DANTZER R, WOLLMAN E, VITKOVIC L et al. Cytokines and depression: fortuitous or causative association? Mol Psychiatry 1999; 4 (4): 328-32.
23. DEBIEN C, DE CHOULY DE LENCLAVE MB, FOUTREIN P et al. Alpha-interferon and mental disorders. Encephale 2001; 27 (4): 308-17.
24. DUNN AJ. Cytokine activation of the HPA axis. Ann NY Acad Sci 2000; 917: 608-17.
25. DUSHEIKO G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26 (Suppl 1): 112S-21S.
26. FATTOVICH G, GIUSTINA G, FAVARATO S et al. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24 (1): 38-47.
27. FINGERHOOD MI, JASINSKI DR, SULLIVAN JT. Prevalence of hepatitis C in a chemically dependent population. Arch Intern Med 1993; 153 (17): 2025-30.
28. FISHER DG, FENAUGHTY AM, PASCHANE AA et al. Hepatitis C virus infection among Alaskan drug users. Am J Public Health 1997; 87 (10): 1722-4.
29. FUKUNISHI K, TANAKA H, MARUYAMA J et al. Burns in a suicide attempt related to psychiatric side effects of interferon. Burns 1998; 24 (6): 581-3.
30. GLEASON OC, YATES WR. Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychosomatics 1999; 40 (6): 510-2.
31. GOLDMAN LS. Successful treatment of interferon alfa-induced mood disorder with nortriptyline. Psychosomatics 1994; 35 (4): 412-3.
32. HO BT, HUO YY, LU JG et al. Opioid-dopaminergic mechanisms in the potentiation of d-amphetamine discrimination by interferon-alpha. Pharmacol Biochem Behav 1992; 42 (1): 57-60.
33. HUNT CM, DOMINITZ JA, BUTE BP et al. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 1997; 42 (12): 2482-6.
34. HURLOCK ECt. Interferons: potential roles in affect. Med Hypotheses 2001; 56(5): 558-66.
35. HURWITZ EL, MORGENSTERN H. Immediate and longterm effects of immune stimulation: hypothesis linking the immune response to subsequent physical and psychological wellbeing. Med Hypotheses 2001; 56 (6): 620-4.
36. JANSSEN HL, BROUWER JT, VAN DER MAST RC et al. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994; 21 (2): 241-3.
37. KAGAYA A, UCHITOMI Y, TAKEZAKI E et al. Plasma levels of cyclic GMP, immune parameters and depressive status during interferon therapy. A prospective study in Japan. Neuropsychobiology 1997; 35 (3): 128-31.
38. KAMATA M, HIGUCHI H, YOSHIMOTO M et al. Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain. Eur Neuropsychopharmacol 2000; 10 (2): 129-32.
39. KAMEI S, TANAKA N, MASTUURA M et al. Blinded, prospective, and serial evaluation by quantitative-EEG in interferon-alpha-treated hepatitis-C. Acta Neurol Scand 1999; 100 (1): 25-33.
40. KASER A, MOLNAR C, TILG H. Differential regulation of interleukin 4 and interleukin 13 production by interferon alpha. Cytokine 1998; 10 (2): 75-81.
41. KINGSLEY D. Interferon alpha for chronic hepatitis C infection. Lancet 1999; 353 (9151): 499 (discussion 500).
42. KOH LK, GREENSPAN FS, YEO PP. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 1997; 7 (6): 891-6.
43. KONSMAN JP, LUHESHI GN, BLUTHE RM et al. The vagus nerve mediates behavioural depression, but not fever, in response to peripheral immune signals; a functional anatomical analysis. Eur J Neurosci 2000; 12 (12): 4434-46.
44. KONSMAN JP, PARNET P, DANTZER R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 2002; 25 (3): 154-9.
45. KRONFOL Z, REMICK DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000; 157 (5): 683-94.
46. LEE DH, JAMAL H, REGENSTEIN FG et al. Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Dig Dis Sci 1997; 42 (1): 186-91.
47. LEONARD BE. The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25 (4): 767-80.
48. LEVENSON JL, FALLON HJ. Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol 1993; 88 (5): 760-1.
49. MADDREY WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999; 19 (Suppl 1): 67-75.
50. MAES M, BONACCORSO S, MARINO V et al. Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. Mol Psychiatry 2001; 6 (4): 475-80.
51. MALAGUARNERA M, DI FAZIO I, RESTUCCIA S et al. Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha. Neuropsychobiology 1998; 37 (2): 93-7.
52. MALISON RT, PRICE LH, BERMAN R et al. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 1998; 44 (11): 1090-8.
53. MATSUSHITA E, UNOURA M, KOBAYASHI K. [Psychiatric complications of interferon therapy. Nipp Rinsho 1994; 52 (7): 1910-3.
54. McALLISTER-WILLIAMS RH, YOUNG AH, MENKES DB. Antidepressant response reversed by interferon. Br J Psychiatry 2000; 176: 93.
55. McHUTCHISON JG, WARE JE Jr, BAYLISS MS et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34 (1): 140-7.
56. MERRICK J. Hepatitis C prevalence in persons with mental retardation. Public Health Rev 1998; 26 (4): 311-6.
57. MEYERS CA, OBBENS EA, SCHEIBEL RS et al. Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease. Cancer 1991; 68 (1): 88-92.
58. MEYERS CA, SCHEIBEL RS, FORMAN AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991; 41 (5): 672-6.
59. MORIKAWA O, SAKAI N, OBARA H et al. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 1998; 349 (2-3): 317-24.
60. MOSSNER R, DANIEL S, SCHMITT A et al. Modulation of serotonin transporter function by interleukin-4. Life Sci 2001; 68 (8): 873-80.
61. MUSSELMAN DL, LAWSON DH, GUMNICK JF et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344 (13): 961-6.
62. OGILVIE AD, BATTERSBY S, BUBB VJ et al. Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet 1996; 347 (9003): 731-3.
63. OKANOUE T, SAKAMOTO S, ITOH Y et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25 (3): 283-91.
64. OWENS MJ, NEMEROFF CB. The serotonin transporter and depression. Depress Anxiety 1998; 8 (Suppl 1): 5-12.
65. PAGUIRIGAN AM, BYRNE GI, BECHT S et al. Cytokine-mediated indoleamine 2,3-dioxygenase induction in response to Chlamydia infection in human macrophage cultures. Infect Immun 1994; 62 (4): 1131-6.
66. PAN W, BANKS WA, KASTIN AJ. Permeability of the blood-brain and blood-spinal cord barriers to interferons. J Neuroimmunol 1997; 76 (1-2): 105-11.
67. PAVOL MA, MEYERS CA, REXER JL et al. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology 1995; 45 (5): 947-50.
68. POLLOCK BG, FERRELL RE, MULSANT BH et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23 (5): 587-90.
69. RABER J, KOOB GF, BLOOM FE. Interferon-alpha and transforming growth factor-beta 1 regulate corticotropin-releasing factor release from the amygdala: comparison with the hypothalamic response. Neurochem Int 1997; 30 (4-5): 455-63.
70. REICHARD O, NORKRANS G, FRYDEN A et al. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351 (9096): 83-7.
71. RIFFLET H, VUILLEMIN E, OBERTI F et al. Suicidal impulses in patients with chronic viral hepatitis C during or after therapy with interferon alpha. Gastroenterol Clin Biol 1998; 22 (3): 353-7.
72. ROHATINER AZ, PRIOR PF, BURTON AC et al. Central nervous system toxicity of interferon. Br J Cancer 1983; 47 (3): 419-22.
73. SAPHIER D, ROERIG SC, ITO C et al. Inhibition of neural and neuroendocrine activity by alpha-interferon: neuroendocrine, electrophysiological, and biochemical studies in the rat. Brain Behav Immun 1994; 8 (1): 37-56.
74. SCALORI A, APALE P, PANIZZUTI F et al. Depression during interferon therapy for chronic viral hepatitis: early identification of patients at risk by means of a computerized test. Eur J Gastroenterol Hepatol 2000; 12 (5): 505-9.
75. SCALORI A, APALE P, ROFFI L. Psychological screening before interferon therapy. Hepatology 2001; 33 (2): 480.
76. SELYE H. Le stress et la vie. Paris: Gallimard; 1956.
77. SENO H, INAGAKI T, ITOGA M et al. A case of seizures 1 week after the cessation of interferon-alpha therapy. Psychiatry Clin Neurosci 1999; 53 (3): 417-20.
78. SHIMIZU H, OHTANI K, SATO N et al. Increase in serum interleukin-6, plasma ACTH and serum cortisol levels after systemic interferon-alpha administration. Endocr J 1995; 42 (4): 551-6.
79. SINGH N, GAYOWSKI T, WAGENER MM et al. Quality of life, functional status, and depression in male liver transplant recipients with recurrent viral hepatitis C. Transplantation 1999; 67 (1): 69-72.
80. SMERALDI E, ZANARDI R, BENEDETTI F et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3 (6): 508-11.
81. SONG C, LIN A, BONACCORSO S et al. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J Affect Disord 1998; 49 (3): 211-9.
82. STRITE D, VALENTINE AD, MEYERS CA. Manic episodes in two patients treated with interferon alpha. J Neuropsychiatry Clin Neurosci 1997; 9 (2): 273-6.
83. SUTER CC, WESTMORELAND BF, SHARBROUGH FW et al. Electroencephalographic abnormalities in interferon encephalopathy: a preliminary report. Mayo Clin Proc 1984; 59 (12): 847-50.
84. TRASK PC, ESPER P, RIBA M et al. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000; 18 (11): 2316-26.
85. VALENTINE AD, MEYERS CA, KLING MA et al. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 1998; 25 (Suppl 1): 39-47.
86. VALENTINE AD, MEYERS CA, TALPAZ M. Treatment of neurotoxic side effects of interferon-alpha with naltrexone. Cancer Invest 1995; 13 (6): 561-6.
87. VALENTINI P, MARIOTTI P, NGALIKPIMA CJ et al. Seizures in an interferon-treated child. Dig Liver Dis 2001; 33 (4): 363-5.
88. VERGASSOLA C, PENDE A, MUSSO NR et al. Effects of interferon alpha-2a on catecholamines and lymphocyte beta 2 adrenoceptors in healthy humans. Int J Neurosci 1990; 51 (3-4): 211-3.
89. WARE JE Jr, BAYLISS MS, MANNOCCHIA M et al. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999; 30 (2): 550-5.
90. WERNER-FELMAYER G, WERNER ER, FUCHS D et al. Characteristics of interferon induced tryptophan metabolism in human cells in vitro. Biochim Biophys Acta 1989; 1012 (2): 140-7.
91. WIRANOWSKA M. Blood-brain barrier and treatment of central nervous system tumors. J Fla Med Assoc 1992; 79 (10): 707-10.
92. WIRANOWSKA M, WILSON TC, THOMPSON K et al. Cerebral interferon entry in mice after osmotic alteration of blood-brain barrier. J Interferon Res 1989; 9 (3): 353-62.
93. WOODFIELD DG, HARNESS M, RIX-TROTT K et al. Identification and genotyping of hepatitis C virus in injectable and oral drug users in New Zealand. Aust NZJ Med 1994; 24 (1): 47-50.
94. YAMANO M, YUKI H, YASUDA S et al. Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice. J Pharmacol Exp Ther 2000; 292 (1): 181-7.
95. YATES WR, GLEASON O. Hepatitis C and depression. Depress Anxiety 1998; 7 (4): 188-93.